Joint Formulary & PAD

Beclometasone with formoterol and glycopyrronium (Trimbow NEXThaler) - Chronic Obstructive Pulmonary Disease (COPD)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Inhaler (dry powder)
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Beclometasone with formoterol and glycopyrronium (Trimbow NEXThaler)
Indication :
Chronic Obstructive Pulmonary Disease (COPD)
Group Name :
Triple therapy
Keywords :
LABA beta agonist, long acting, ICS, antimuscarinic, triple therapy
Brand Names Include :
Trimbow NEXThaler
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
2

Committee Recommendations (1)

The Surrey Heartlands Area Prescribing Committee has agreed Trimbow® NEXThaler® as an option where triple therapy is indicated in the treatment of COPD. See COPD Guidelines for more information.

The locally preferred triple-therapy devices for COPD are:

Low carbon:
Trimbow NEXThaler (dry powder)
Trelegy Ellipta (dry powder)

Alternative devices:
Trimbow (pMDI). To be used with a spacer.

Prescribe devices by brand.

Other Indications

Below are listed other indications that Beclometasone with formoterol and glycopyrronium (Trimbow NEXThaler) is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Chronic Obstructive Pulmonary Disease (COPD).